Stockwinners Market Radar for April 20, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:18 EDT Viper Energy holder Blackstone sells 1.81M shares - Blackstone Holdings III LP (BX) disclosed in a regulatory filing the sale of 1,810,400 shares of Viper Energy Partners (VNOM) on April 18 at an average price of $30.03 for proceeds of $54,359,976.

20:04 EDT Cathie Wood's ARK Investment bought 61.8K shares of Roku today

19:04 EDT BHP Group affirms FY23 Iron Ore output view of 249MT-260MT - Affirms FY23 Copper output 1,635-1,825kt and metallurgical coal output of 29-32MT.

18:50 EDT Vallon Pharmaceuticals stockholders approve GRI Bio merger, reverse stock split - Vallon Pharmaceuticals stockholders have approved Proposals 1, 2, 4 and 5, related to the proposed merger with GRI Bio, a privately held biotechnology company, at a special meeting of stockholders held on April 20. Accordingly, at the effective time of the merger, each share of GRI's common stock will be automatically converted into the right to receive a number of shares of Vallon's common stock equal to the exchange ratio, as calculated pursuant to the merger agreement. The exchange ratio is 0.0374. Vallon's stockholders also approved a reverse stock split of shares of Vallon's common stock at a ratio anywhere in the range of not less than 1 new share for every 15 shares and not greater than 1 new share for every 40 shares outstanding. Vallon's board of directors has set the Reverse Split ratio at 1-for-30. In connection with the execution of the merger agreement, Altium Capital agreed to invest approximately $15M at a pre-money valuation of $75M of which $2.5M has already been invested and an additional $12.25M will be invested coincident with the close of the merger. The combined company is expected to use the proceeds from the financings to fund the advancement of GRI Bio's Natural Killer T development pipeline into mid-2024 with an initial focus on idiopathic pulmonary fibrosis. The closing of the merger is anticipated to take place on April 21. The merger would result in a combined company which will operate under the name "GRI Bio, Inc." and will focus on advancing GRI Bio's pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. The shares of company common stock previously trading on Nasdaq through the close of business on April 21 under the ticker symbol "VLON," are expected to commence trading on The Nasdaq Capital Market, on a post-Reverse Split adjusted basis, under the ticker symbol "GRI", effective April 24.

17:50 EDT Equifax receives CID from CFPB amid consumer dispute probe - Equifax received a Civil Investigative Demand or CID, from the CFPB as part of its investigation into our consumer disputes process in order to determine whether we have followed the FCRA's requirements for the proper handling of consumer disputes. The CID requests the production of documents and answers to written questions. We are cooperating with the CFPB in its investigation and are in discussions with the CFPB regarding our response to the CID. In addition, in January 2023, the CFPB informed us that its enforcement division will be investigating our previously-disclosed coding issue identified within a legacy server environment in the U.S. slated to be migrated to the new Equifax cloud infrastructure which impacted how some credit scores were calculated during a three-week period in 2022. We are cooperating with the CFPB in its investigation. At this time, we are unable to predict the outcome of these CFPB investigations, including whether the investigations will result in any actions or proceedings against us. This information was accesses in a company regulatory filing.

17:10 EDT Predictive Oncology announces reverse stock split - Predictive Oncology announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The reverse stock split will become effective at 12:01 a.m. on Monday, April 24, 2023. Predictive Oncology's common stock will continue to be traded on the Nasdaq Capital Market under the symbol POAI and will begin trading on a split-adjusted basis when the market opens on Monday, April 24, 2023. The new CUSIP number for the Company's common stock following the reverse stock split will be 74039M309. The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement to maintain the listing of the Company's common stock on the Nasdaq Capital Market. At a reconvened special meeting of stockholders held on April 19, 2023, Predictive Oncology's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of Predictive Oncology's common stock through an amendment to its Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-25, such ratio to be determined by the Company's Board of Directors.

16:40 EDT Aziyo Biologics in distribution pact with LeMaitre for U.S cardio products - Aziyo Biologics (AZYO) announced it has entered into a distribution agreement with LeMaitre Vascular (LMAT) a provider of vascular devices, implants and services. Under the agreement terms, Aziyo will grant LeMaitre exclusive U.S. distribution rights for the products within its cardiovascular segment: "We are thrilled to collaborate with LeMaitre, an established leader in the vascular space, to distribute our cardiovascular surgery products," said Dr. Randy Mills, President and Chief Executive Officer of Aziyo. "Our products are designed to be highly efficacious across a wide range of applications, and we look forward to expanding their availability by leveraging LeMaitre's much larger commercial organization. This partnership should increase our operational efficiency as we focus our commercial resources behind our CanGaroo Envelope, which is utilized to help reduce complications associated with implantable electronic devices such as pacemakers, defibrillators and neuromodulation devices."

16:20 EDT Park Aerospace enters cooperation agreement with Huffman Prairie - Park Aerospace announced that it has entered into a cooperation agreement with Huffman Prairie Holdings and related entities under which the company plans to nominate Shane Connor, Huffman Prairie's managing partner, for election as a director of the company at its upcoming 2023 annual shareholders meeting.

16:19 EDT Aspen Aerogels files patent infringement lawsuit against Beerenberg - Aspen Aerogels announced that it has filed actions against Beerenberg Services AS, Beerenberg Korea Ltd., their Singaporean supplier and their Chinese aerogel manufacturer related to the unlawful import and sale of allegedly infringing aerogel products. Aspen filed an action for patent infringement in the Seoul Central District Court and also an action for unfair trade practices in the Korea Trade Commission. Beerenberg's aerogel blanket product is believed to infringe several of Aspen's patents related to high performance reinforced aerogel compositions. Additionally, Aspen has alleged that Beerenberg is infringing the Korean counterparts of patents previously enforced successfully by Aspen against Chinese aerogel manufacturers in Germany and the United States. Aspen is seeking injunctive relief and monetary damages against the defendants. "Our patent portfolio has been consistently validated in courts across the United States, Europe and Asia. Chinese-made aerogel products have been found to infringe our patents in multiple jurisdictions globally. With the filing of this action against Beerenberg, we again send a clear message to the markets that we will continue to aggressively enforce our intellectual property rights against any importer, distributor, reseller or customer of aerogel products that infringe our patents," said Donald R. Young, President and CEO of Aspen.

16:18 EDT Valmont announces $400M share buyback

16:10 EDT Allogene Therapeutics appoints Timothy Moore as chief technical officer - Allogene Therapeutics announced the appointment of Timothy Moore to executive VP, chief technical officer effective April 24. The selection of Moore, the former executive VP, technical operations of Kite Pharma responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the company's mission to being the first to bring an AlloCAR T product to market. Moore succeeds Alison Moore, who intends to serve as a consultant to Allogene.

16:07 EDT Saia opens LTL Freight terminal in Georgia - Saia opened its new Saia LTL Freight terminal in Buford, Georgia with a ribbon cutting ceremony as it seeks to get closer to customers located throughout the Metro Atlanta area.

16:05 EDT Seacoast Banking increases quarterly dividend to 18c per share - Seacoast Banking announced that the company's board of directors declared a quarterly cash dividend to the holders of the company's common stock and approved a quarterly increase from 17c to 18c per share. The dividend is payable on June 30 to shareholders of record at the close of business on June 15.

16:02 EDT Janux Therapeutics announces first patient dosed with JANX008 in Phase 1 trial - Janux Therapeutics announced the first patient has been dosed at City of Hope in a Phase 1 clinical trial of JANX008 in subjects with advanced or metastatic solid tumors including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. JANX008 is an epidermal growth factor receptor directed T cell engager and is the second product candidate utilizing Janux's TRACTr platform to be administered in humans. "We are excited to initiate the clinical evaluation of our second product candidate from our TRACTr platform. JANX008 is designed to achieve tumor-selective T-cell activation and tumor killing while sparing healthy tissues," said Wayne Godfrey, M.D., Chief Medical Officer at Janux. "Our preclinical data with JANX008 demonstrated tumor growth inhibition and lower toxicity levels, when compared to an unmasked T cell engager."

15:22 EDT MAIA Biotechnology jumps over 2% after survival data in patients with NSCLC - Shares of MAIA Biotechnology are up over 2% or 8c per share to $3.61 in late day trading on Thursday after the company announced earlier, preliminary survival data in the Part A safety lead-in of its ongoing phase 2 trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer NSCLC. The first 2 patients enrolled in Part A of the study continue to be alive, approximately 10 and 9 months respectively, from treatment initiation. Both patients have advanced Stage IV metastatic disease and are heavily pretreated, receiving third and fourth line of therapy respectively after previously failing treatment with an immune checkpoint inhibitor. "The current treatment options in patients with advanced relapsed or refractory NSCLC who failed two or more therapy regimens are limited and show minimal benefit. Furthermore, discontinuation of treatment is rapidly followed by physical decline and death, therefore seeing patients with such survival and no disease progression in this clinical setting, is noteworthy," says MAIA's Chief Medical Officer Mihail Obrocea.

15:08 EDT SL Green Realty CEO says 'market to consummate' deals with relatively low LTVs - Asked about loan-to-value, or LTV, ratios on the company's Q1 earnings call, SL Green CEO Marc Holliday said: "I'd say if we have a successful conclusion, then what we'll learn or reaffirm is that for good sponsors, good assets, good locations with relatively low LTVs, there's a market to consummate that deal. Yes, I would say we've learned that. I'd say that we just maybe be confirmatory if we can get that done." Asked the follow-up question "And then I guess just in general, how are lenders thinking about LTV in general?", Holliday responded: "The lenders are probably in about 5 to 10 percentage points from, let's call it, the peak of the liquid market. So much more in that 50% to 55% LTV range."

14:58 EDT Elite Pharmaceuticals files ANDA with FDA for generic antimetabolite drug - Elite Pharmaceuticals announced earlier on Thursday, that it filed an Abbreviated New Drug Application, ANDA, with the US Food and Drug Administration or an undisclosed generic drug product in a class of medications called antimetabolites. IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product.

14:05 EDT Freightos reports 229K transactions booked in Q1 vs 211K in Q4 - Freightos Limited reported Q1 2023 Key Performance Indicators. Financial results will be reported separately. Transactions 229,211 vs management's expectations of 218,500 - 225,000. A record 229K transactions were booked on the platform in Q1 2023, up from 211K in Q4 2022 and 114K in Q1 2022. This exceeded the high end of management's expectations by 2% and represented an 8.8% increase compared to the previous quarter, despite market softness and the first quarter being the normally seasonally weak quarter for the industry. Freightos has experienced record platform Transaction growth for the previous 13 consecutive quarters. Despite market conditions, GBV exceeded management expectations as a result of strong Transaction growth. This growth was supported by an increase in both demand - users booking across the platform - and supply - carriers offering their services on the platform. The number of Unique buyer users digitally booking freight services across the Freightos Platform grew 29% compared to Q1 2022, reaching 16,226. Carriers selling on the platform, primarily on WebCargo, reached 37 in Q1 2023, up 19% year over year.

14:01 EDT Lithium Americas completes acquisition of Arena Minerals - Lithium Americas announced the completion of the previously announced plan of arrangement whereby Lithium Americas has acquired all of the issued and outstanding common shares of Arena. Arena owns 65% of the Sal de la Puna project covering approximately 13,200 hectares of the Pastos Grandes basin located in Salta, Argentina. "With the completion of the acquisition, we have taken a big step towards consolidating the Pastos Grandes basin. While our focus remains on near-term startup of production at Cauchari-Olaroz, the addition of Arena provides increased flexibility as we continue to advance our growth plans in Argentina," said John Kanellitsas, Vice Chairman of Lithium Americas.

13:53 EDT Cumberland County court says Avangrid's NECEC project may lawfully proceed - The following is a statement from Scott Mahoney, Senior Vice President - General Counsel at AVANGRID regarding today's decision by a Cumberland County jury: "The jury's unanimous verdict affirms the prior rulings of the Maine Supreme Judicial Court that the New England. Clean Energy Connect NECEC project may lawfully proceed. Even after repeated delays and the costs caused the change in law, the NECEC project remains the best way to bring low-cost renewable energy to Maine and New England while removing millions of metric tons of carbon from our atmosphere each year."

13:36 EDT Micron enters settlement agreement with DOJ over employment discrimination - The Justice Department announced it has secured a settlement agreement with Micron Technology. The settlement resolves the department's determination that Micron violated the Immigration and Nationality Act by discriminating against a U.S. citizen when it failed to hire him for a position and instead hired a temporary visa worker. The department's investigation began when a U.S. citizen worker complained that Micron unfairly denied him employment because of his citizenship status. The department determined that Micron unlawfully preferred a temporary visa worker for the position, failing to meaningfully consider the U.S. citizen's qualifications. Under the INA, employers cannot discriminate based on citizenship, immigration status or national origin at any stage of the hiring process, unless required or allowed by law. Under the settlement, Micron will pay a civil penalty to the United States and offer back pay totaling $85,000 to the affected worker. Additionally, Micron will train its staff on the INA's anti-discrimination provision, change its policies and procedures and be subject to departmental monitoring for a two-year period. Reference Link

13:17 EDT Alphabet's Google merges AI resources, announces Google DeepMind - Alphabet's Google has merged its two main artificial-intelligence research units. The new unit, Google DeepMind, combines the existing Google Brain and DeepMind research groups into one team. In a blog post, Google and Alphabet CEO Sundar Pichai says that, "To ensure the bold and responsible development of general AI, we're creating a unit that will help us build more capable systems more safely and responsibly. This group, called Google DeepMind, will bring together two leading research groups in the AI field: the Brain team from Google Research, and DeepMind... Combining all this talent into one focused team, backed by the computational resources of Google, will significantly accelerate our progress in AI. As CEO of Google DeepMind, Demis Hassabis will lead the development of our most capable and responsible general AI systems - research that will help power the next generation of our products and services. Jeff Dean will take on the elevated role of Google's Chief Scientist, reporting to me... Google Research will continue its important work leading fundamental advances in computer science across areas such as algorithms and theory, privacy and security, quantum computing, health, climate and sustainability and responsible AI, and will report in to James Manyika along with his existing Tech & Society teams." Reference Link

13:08 EDT Sony Interactive Entertainment to acquire Firewalk Studios; terms not disclosed - Sony Interactive Entertainment announced it has entered into an agreement with ProbablyMonsters Inc. to acquire Firewalk Studios, a studio developing an original AAA multiplayer game for PlayStation 5 and PC. Firewalk was formed in 2018 as part of ProbablyMonsters. With nearly 150 employees and growing, Firewalk's day-to-day operations post-acquisition will continue to be run by the studio's management team in collaboration with PlayStation Studios External Development team. Terms of this transaction, including the acquisition cost, are not disclosed due to contractual commitments.

13:06 EDT Live Nation introduces Vibee, a music-led destination experience company - The company said, "Vibee, the new music-led destination experience company, has officially arrived and is transforming the way fans travel and connect with their favorite artists. Founded by Live Nation, Vibee builds unforgettable immersive trips for music lovers in the most sought after destinations around the world. Vibee is launching with confirmed partnerships with many of the industry's most respected live event and festival producers including Insomniac, C3 Presents, Country Nation as well as other Live Nation festival properties. The company aims to create a range of opportunities that are both cross-generational and genre diverse, from multi-day events & activations on land and sea, to bespoke festival & residency packages."

13:02 EDT Cameco signs ten-year nuclear fuel agreement in Bulgaria - Cameco has signed a 10-year supply contract to provide sufficient volumes of natural uranium hexafluoride, or UF6, to meet the full requirements of the Kozloduy 5 Reactor at the Kozloduy Nuclear Power Plant, the only nuclear generating station in the Republic of Bulgaria. The agreement, running through 2033, will see Cameco deliver a total of approximately 2.2 million KgU as UF6.

12:50 EDT Sunlight jumps 28% to 42c after Bloomberg says Pagaya exploring buyout

12:06 EDT Casa Systems selected by LG U+ for virtualized Home eNodeB Gateway solution - Casa Systems announced that LG U+ selected its virtualized Home eNodeB Gateway solution to "help the South Korean operator modernize its network infrastructure and unlock new services and revenue streams as part of its broader network and service strategy." Gibson Ang, Vice President of Technology at Casa Systems, said: "As LG U+ looked to scale the reach, performance and security of its corporate services, it recognized the value of Casa Systems' fully virtualized HeNB GW and SeGW solution featuring unmatched performance from a small footprint, enabling them to cost-effectively scale services. E-Tech System is a leader in the industry with a long history of delivering innovative software-based solutions and services to its customers. We look forward to working with E-Tech System on this and opening new doors for other deployments in Korea that would benefit from our 4G/5G cloud-native solutions."

12:00 EDT Xortx Therapeutics' oxypurinol receives FDA orphan designation - Xortx Therapeutics' oxypurinol received FDA orphan designation as a treatment of autosomal dominant polycystic kidney disease, according to a post to the agency's website. Reference Link

12:00 EDT Getty Images falls -12.6% - Getty Images is down -12.6%, or -80c to $5.54.

12:00 EDT Sunnova Energy rises 11.0% - Sunnova Energy is up 11.0%, or $1.74 to $17.57.

12:00 EDT Studio City rises 18.0% - Studio City is up 18.0%, or $1.37 to $8.98.

11:41 EDT Norsk Hydro announces end of labor dispute between NHO, LO - The company said, "The Norwegian Labor Union and The Confederation of Norwegian Enterprise have agreed today on a solution to the labor dispute that led to a strike on Monday, April 17. Hydro Karmoy and Hydro Ardal will resume normal operations and shipping of products to customers will be resumed. The financial consequences for the company and delays to customers are expected to be limited."

11:27 EDT BuzzFeed announces departure of COO Christian Baesler - BuzzFeed announced that Christian Baesler, its Chief Operating Officer and the CEO of Complex Networks, will be departing the company, effective April 28, in order to pursue other opportunities. Subsequently, BuzzFeed's President, Marcela Martin, who joined the company in August 2022, will assume responsibility for all revenue functions.

11:14 EDT United Bancorp raises quarterly cash dividend to 16.50c per share - On April 19, 2023, the Board of Directors of United Bancorp declared a second quarter dividend payment of 16.50c per share for shareholders of record on June 9, 2023 with a payment date of June 20, 2023. This is an increase of 1c, or 6.5%, over the regular cash dividend paid in the second quarter of last year.

10:58 EDT Braskem SA trading resumes

10:43 EDT Shift4 Payments says short report 'got it wrong' in 'many plain, obvious ways' - In a letter to shareholders that was emailed to The Fly as well, Shift4 Payments CEO Jared Isaacman said in part, "As some of you may have seen, we were the subject of a short seller's report yesterday... We knew long before our first day at the New York Stock Exchange that operating a public company attracts critics, both fairly and unfairly. I don't fault these cynics for trying to do their job, but they've got it wrong on FOUR and in many plain and obvious ways. As just a few examples: - I only purchased shares in 2022 and never sold stock on the market as it was implied. My share count diminished in 2022 as a result of stock donations to St. Jude Children's Research Hospital. - I have never received a margin call, even when the share price was at its lowest last summer. In fact, I refinanced and reduced the size of my margin loan in December of 2022, well above the 52-week lows. - As discussed at length, insourcing distribution was a fantastic way to improve the customer experience, margins, free cash flow and the unit economic model of our new SkyTab POS product... I am and will continue to be the largest shareholder for the foreseeable future - and simply because I believe in our ability to keep winning. For more than two decades, our growth and audited financial results, including our free cash flow generation, speak for themselves. We plan to have a detailed discussion of our Q1 operating results and financial performance in two weeks. For those betting against us, keep in mind May 4th is just around the corner."

10:26 EDT Google offers billing choice for U.K. Play Store developers - Following an antitrust intervention by the U.K.'s Competition and Markets Authority, or CMA, Google has proposed allowing developers offering apps through its U.K. Play mobile app store to have the option to use third-party payment processors for in-app transactions. In a blog post, legal director, Oliver Bethell, writes that, "In June 2022, the United Kingdom's Competition and Markets Authority (CMA) announced that it had launched an investigation into payment systems for in-app purchases through Google Play on Android devices. Since then, we have engaged with the CMA in constructive conversations, and today we are announcing a set of potential commitments in relation to our billing policies in the U.K to resolve the CMA's investigation... Building on our experience of offering users a choice of billing systems in the EEA and other parts of the world, the commitments would see us roll out user choice billing in the U.K. Under the commitments, developers will be able to add an alternative in-app billing system, alongside Google Play's billing system, for their mobile and tablet users in the U.K. At checkout, users will be able to choose which billing system to use. These options will be presented in a neutral manner allowing users to make an informed and engaged choice. Developers can alternatively choose to not offer Google Play billing at all when their users in the U.K. are paying for digital content and services. The service fees for distributing apps via Android and Google Play will continue to be based on digital sales via our platform. The service fee is how we support our ongoing investments in Android and Google Play, reflects the value provided by Android and Google Play, and is how we earn money as a business. When a user selects alternative billing, we will reduce the developer's service fee by 4%. When developers choose not to offer Google Play billing at all , the service fee the developer pays will be reduced by 3%. For both options, developers are still required to meet appropriate user protection requirements, and service fees and conditions will continue to apply in order to support our investments in Android and Play. Our proposal is for these commitments to be phased in. They will first be made available to developers of non-gaming apps should the commitments be accepted by the CMA following the public consultation. Following this, the roll out of these commitments to gaming apps will come into effect no later than October 2023. This will ensure a smooth transition for developers and to allow for the necessary changes to be made to our systems."Reference Link

10:23 EDT Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation - Incyte announced that the European Commission has granted a marketing authorization for Opzelura cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. "Opzelura is the first and only approved treatment in the European Union to offer support for repigmentation in eligible patients with non-segmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin and reduced quality of life," the company stated.

10:00 EDT Nokia falls -8.5% - Nokia is down -8.5%, or -40c to $4.22.

10:00 EDT Griffon falls -15.5% - Griffon is down -15.5%, or -$4.91 to $26.70.

10:00 EDT D.R. Horton rises 7.1% - D.R. Horton is up 7.1%, or $7.20 to $109.06.

10:00 EDT Petros Pharmaceuticals trading resumes

09:47 EDT Insteel falls -7.6% - Insteel is down -7.6%, or -$2.11 to $25.61.

09:47 EDT Griffon falls -14.6% - Griffon is down -14.6%, or -$4.61 to $27.00.

09:47 EDT Calix rises 9.9% - Calix is up 9.9%, or $4.78 to $53.24.

09:35 EDT GE HealthCare receives FDA 510(k) clearance for CARESCAPE Canvas platform - GE HealthCare announced US FDA 510(k) clearance of its CARESCAPE Canvas patient monitoring platform for precise, flexible patient care. The company said, "CARESCAPE Canvas and CARESCAPE ONE are part of an adaptable ecosystem that can easily scale up and scale down monitoring capabilities based on the acuity of each individual patient, delivered on a standardized platform that drives enterprise efficiency and ease of service."

09:30 EDT Diana Shipping announces signing, drawdown of $100M term loan facility - Diana Shipping announced that on April 12, 2023, it signed a term loan facility with Danish Ship Finance A/S for up to $100 million with maturity date in April 2028. Yesterday, it concluded the drawdown of $100 million, secured by nine vessels. The proceeds from the loan facility refinanced other loan facilities with an aggregate outstanding amount of approximately $87 million, namely two existing loan facilities with BNP Paribas of approximately $75.2 million and another loan facility with DNB Bank ASA of approximately $11.8 million related to the same nine vessels. The remaining proceeds may be used to pay transaction costs and expenses incurred in connection with the loan agreement and/or general corporate purposes.

09:22 EDT Mangoceuticals featured on Webull Corporate Communication platform - Mangoceuticals is now participating on the new Webull Corporate Communication services platform.

09:20 EDT Arcimoto appoints Chris Dawson as CEO - Arcimoto announced that Christopher Dawson has been appointed to the role of CEO effective immediately. Mr. Dawson joined the Company's Board in August of 2022 and will continue to serve as a director. Jesse Fittipaldi, who had served as Interim CEO, has been named President, reporting directly to Mr. Dawson. Dwayne Lum who has served as Chief Product Officer will be assuming the role of COO and Terry Becker who serves as a Board Director will head up the Tilting Motor Works Division and TRiO product family. Doug Campoli who had served as CFO left the company April 14th. Dawson most recently served as the Chief Executive Officer of Nikola Tesla Co.

09:18 EDT BAE Systems signs contract with Norway's Ritek to produce two new CV90 variants - BAE Systems has signed a contract with Norwegian company Ritek to produce two new CV90 variants for the Swedish Armed Forces. The work will be carried out in cooperation with BAE Systems Hagglunds, the designer and producer of the CV90 family of vehicles."This new contract to supply Norwegian produced CV90s to the Swedish Armed Forces is proof of the potential opportunities of this partnership."

09:16 EDT Statera BioPharma, Biostax reach dispute settlement, amended license agreement - Immune Therapeutics and Statera Biopharma announced that the Board of Directors of both companies has approved both a joint petition to dismiss the involuntary bankruptcy case with Statera and an amended royalty-bearing license agreement between Biostax and Statera for select Statera intellectual property. Under Amendment No. 3 to the License Agreement, Biostax will pay royalties to Statera and obtain worldwide exclusive rights to numerous patents surrounding Low-dose Naltrexone and Met-enkephalin, for all indications except Crohn's Disease, which Statera will continue to develop and commercialize. .

09:15 EDT Ascent Solar secures $9M equity financing with Lucro Investments - Ascent Solar Technologies announced that it has entered into a $9M equity financing agreement with Singapore-based Lucro Investments. Under the Agreement, Lucro will purchase 7,499,997 shares of Ascent common stock at a purchase price of $1.20 per share. The Company will receive the financing in monthly installments of $1 million. The proceeds of the investment will be used for general business operations and working capital for future initiatives. "We are pleased to announce an additional funding commitment from Lucro Investments, at an inflection point in our Company's history. Ascent is undergoing significant and transformative changes, as we continue to guide the Company towards providing our flexible, lightweight, and durable thin-film solar solutions to an expanded spectrum of audiences on an international stage," said Jeffrey Max, Chief Executive Officer of ASTI. "This new investment commitment from Lucro Investments signals a strong vote of confidence for our burgeoning Company and strategy as we advance our capabilities, output and channels."

09:13 EDT Ispire Technology announces strategic partnership with Cookies - Ispire Technology announced a strategic partnership with Cookies, an international cannabis lifestyle brand. Under the terms of the supply agreement, Cookies will work with Ispire in good faith to help facilitate the purchase of an aggregate 15 million units of mutually agreed Ispire products by Cookies' third-party retail and wholesale partners. Ispire will also provide a dedicated product team to support Cookies' product needs. "We are pleased to be partnering with Cookies, the globally renowned cannabis company, to supply their customers with our CBD vaping products at competitive prices," said Michael Wang, CFO of Ispire. "We strongly believe that Ispire offers the very best products in the large and rapidly growing marketplace for CBD and cannabis vaping and look forward to embarking on this mutually-beneficial relationship."

09:11 EDT Nuvei selected by Cart.com as its exclusive payments partner - Nuvei announces that it has been selected as the exclusive payments partner of Cart.com, a leading eCommerce software and service provider that enables retail brands to easily sell and fulfill across every channel globally. Cart.com customers will be able to enhance their payments through Nuvei for Platforms, Nuvei's fully customizable solution that enables companies of any size to embed enterprise-level payments technology into their online operations. Nuvei Chair and CEO Philip Fayer commented: "We're excited to be partnering with Cart.com, one of the premier platforms driving the evolution of eCommerce. We have a shared belief that businesses of any size should be able to compete with the global eCommerce giants on a level playing field when it comes to the quality of their technology and payments solutions."

09:10 EDT JetBlue announces Puerto Rico expansion with two new routes - JetBlue announced two new routes from Puerto Rico, bringing more low-fare, high-quality flights to "La Isla del Encanto". Launching this summer, and out for sale , JetBlue will now offer year-round service from Luis Munoz Marin International Airport SJU in San Juan, Puerto Rico to Raleigh-Durham International Airport RDU in North Carolina, and from Rafael Hernandez International Airport BQN in Aguadilla, Puerto Rico to Tampa International Airport TPA in Florida. "As the largest airline in Puerto Rico, we are thrilled to continue diversifying our network and to further grow JetBlue's presence on the island with the addition of these two new routes," said Robin Hayes, chief executive officer, JetBlue. "This growth will increase competition and choice for customers traveling to and from Puerto Rico and for travelers in Raleigh and Tampa, while also building on our commitment to support tourism on the island and connect family and friends. We look forward to delivering even more of the much-loved JetBlue experience - with our unique combination of low fares and award-winning service - to our customers traveling between Puerto Rico and the U.S. mainland following the successful completion of our combination with Spirit."

09:08 EDT iSun awarded $7.7M contract for 2.2MW solar carport in Ohio - iSun announced that it has received a 2.2 MW, $7.7M contract to provide a solar carport to one of the nation's largest financial institutions at a single location in Ohio. Highlights include:$7.7M solar carport contract highlights iSun's ability to originate projects and create value for new customers, including through turnkey engineering services ;2.2 MW contract expands iSun's growing EV Infrastructure presence into the Ohio market Project scheduled to begin in Q2 2023 and will be added to iSun's existing backlog of projects. "We are excited to continue our strong start to 2023 with a new contract award for a solar carport for a global company," said Jeffrey Peck, Chairman and Chief Executive Officer of iSun. "This new project is particularly rewarding as it highlights the value creation our team can provide based upon our differentiated ability to originate solar projects. This project also underscores our flexibility in originating projects across all our segments, including EV Infrastructure, to provide our customers with the products and services they require. These business development efforts are driving our continued growth by building new customer relationships that allow us to enter new markets efficiently. We appreciate the trust and confidence of our customers in our ability to help them achieve their goals in alternative energy initiatives."

09:06 EDT Mullen Automotive announces test results of recently acquired JV technology - Mullen Automotive announces test results of its recently acquired joint venture, JV, technology. Element Materials Technology test results indicate that the Energy Management Module technology substantially increases the driving range and efficiency of any current EV battery. Specific vehicle testing of a high-volume OEM electric vehicle by Element resulted in a calculated increase in range from 269 to 431 miles, which is a 60% increase in efficiency. EMM technology was also tested by Mullen Automotive engineers on the Company's Class 1 EV Cargo Van at its Troy, Michigan, facility. Results showed more than a 75% increase in range for the 42-kWh lithium-ion battery pack, which would be a calculated EPA estimated range of 186 miles at a very low added cost and mass. EMM technology is being integrated into final stages of product development and is planned to be introduced in all Mullen commercial and consumer vehicle programs. "Seeing the previous EMM test results conducted by Element, along with Global EVT testing, and correlating that with testing by our engineers, we believe this technology is a perfect fit for Mullen's EV product lineup as well as the advancement in EV technology for the overall automotive industry," said David Michery, CEO and chairman of Mullen Automotive. "Mullen Advanced Energy Operations plans on licensing this technology to anyone who uses an electric vehicle."

09:04 EDT Cognizant selected by Horizon to support government healthcare programs - Cognizant has been selected by Horizon Healthcare Services to support its government healthcare programs. As part of a 7-year renewal agreement, Cognizant will manage Horizon's claims processing, encounters submissions to the state, provider configuration, and enrollment services for its 1.2M Medicaid and Dual Eligible Special Needs Plan members. Cognizant will leverage its TriZetto healthcare products suite to provide end-to-end support for Horizon, including hosting the insurer's operations on its Facets platform. By utilizing advanced automation solutions, Cognizant will help Horizon expedite the claims payment process and ensure accuracy in support of excellent member-provider experiences.

09:04 EDT Outbrain appoints Maman as CTO, Tori as CPO - Outbrain announced the appointment of Yonatan Maman as Chief Technology Officer, CTO, and Andraz Tori in a newly created executive role as Chief Product Officer, CPO. Co-Founder, Chief Technology Officer, and General Manager, Israel, Ori Lahav, will transition his responsibilities and focus on cross-company strategic initiatives, while continuing his role as General Manager, Israel. Maman joined Outbrain in 2011 as a Senior Software Engineer and has served as Vice President of Engineering for the past five years. Tori has served as Head of Recommendations and Data Science at Outbrain for the past four years, following Outbrain's acquisition of Zemanta, of which he was a founder.

09:02 EDT PepsiCo's Frito-Lay to deploy over 700 EVs by end of 2023 - Frito-Lay announced it will deploy over 700 electric delivery vehicles in the U.S. by the end of 2023. The vehicle deployments are expected to lower emissions by 7,052 metric tons of greenhouse gas emissions annually, equivalent to 1,533 passenger cars removed from the road. Paired with advancements in regenerative agriculture, water saving technology, packaging innovation and more, the move reflects the PepsiCo division's significant progress toward its PepsiCo Positive sustainability goals.

09:01 EDT LPL Financial: Sheehan Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial LLC announced that financial advisors James Sheehan, and Shawn Tighe have joined LPL Financial's broker-dealer, RIA and custodial platforms. They become the 30th team to join LPL Strategic Wealth Services, the firm's modern supported independent solution that enables advisors to grow their business according to their vision. The advisors reported having served approximately $450 million in advisory and brokerage assets, and they join LPL from Raymond James.

08:53 EDT Augmedix spikes 85% in pre-market after announcing pact with HCA Healthcare - Shares of Augmedix (AUGX) are up 85% at $3.34 in pre-market trading after the company announced a partnership with HCA Healthcare (HCA) to accelerate development of AI-powered technology that "aims to transform the way patient care is documented in the acute care setting".

08:49 EDT XPO Logistics names Dave Bates as COO - XPO (XPO) announced that Dave Bates is joining the company as chief operating officer, North American LTL, effective April 21, 2023. Bates joins XPO from 27 years with Old Dominion Freight Line (ODFL) where he was responsible for all day-to-day operations in North America for the last 12 years as senior vice president, operations.

08:46 EDT Conduent partners with Jopari Solutions on claims management technology - Conduent announced the launch of the Shield Provider Portal, a new self-service technology solution that enables medical providers to view the adjudication status and payment information related to workers compensation and auto casualty claims across multiple payers. The Shield Provider Portal is offered through a collaboration with Jopari Solutions.

08:45 EDT Lisata Therapeutics receives $2.2M of capital through New Jersey program - Lisata Therapeutics announced that it has received $2.2 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority, NJEDA. The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their New Jersey net operating losses, NOLs, and research and development tax credits to unrelated qualifying corporations. "We are delighted to once again be chosen to participate in the New Jersey NOL program, which allows us today to convert certain state operating losses into tangible working capital," stated David J. Mazzo, Ph.D., Chief Executive Officer of Lisata. "We appreciate the NJEDA's ongoing support of the New Jersey biopharma community under this program, through which we have cumulatively received nearly $18 million of non-dilutive funding over the past four years. This capital will be allocated towards further advancement of the Company's clinical development programs."

08:43 EDT Sterling Construction gets $70M design-build transportation solution award - Sterling Infrastructure announced that Ralph L. Wadsworth Construction Company was awarded a $70M design/build contract for the Yellowstone River Bridge Project. The project began in April 2023 and is expected to finish at the end of 2026. The Yellowstone River Bridge project is funded by the Federal Highway Administration and will replace an existing 60-year-old bridge on a new mile-long realignment of the Northeast Entrance Road in Yellowstone National Park. The new one-quarter mile, 175-foot-high bridge will have decking, sidewalks, and railing. It is located within a hydrothermally and geothermally active zone and will require specialized cement and thermal monitoring of below grade concrete curing. Multiple temporary bridges will be constructed for construction access over streams and environmentally sensitive areas. This award will be included in March 31, 2023 backlog.

08:43 EDT AT&T says 'particularly proud' of quality of subscriber additions - Says churn is "historically low." Says "executing well" on go to market strategy. Expects to further accelerate cost take outs as the year progresses. Says continues to invest in 5G networks at "record levels." Says testing AI in customer service, fleet development. Says seeing "moderation of growth" in wireless segment. Comments taken from Q1 earnings conference call.

08:42 EDT Wave Life Sciences announces preclinical data published on siRNA designs - Wave Life Sciences announced the publication of preclinical data for the company's small interfering RNA, siRNA, designs in the journal Nucleic Acids Research. Data reported include an in vivo study where a Wave subcutaneously administered, GalNAc-conjugated siRNA maintained approximately 80% silencing of HSD17B13 transcripts for three months in the liver of transgenic mice, while a comparator siRNA format lost silencing activity at the same timepoint. "Wave has built the most versatile RNA medicines platform in the industry, with multiple modalities to optimally address disease biology. We continue to lead the field in RNA editing with our alpha-1 antitrypsin deficiency program and are also advancing a differentiated exon skipping portfolio in DMD, led by WVE-N531 for those amenable to exon 53 skipping. With RNAi, we have opened up a whole new capability set. The data in this publication, coupled with our recent unconjugated siRNA data showing 70-90% mRNA silencing and broad tissue exposure across six brain regions in mice,1 demonstrate our potential for achieving best-in-class silencing," said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. "We expect our work in RNAi to deliver near-term value through collaborations, including our active research collaboration with GSK." Wave's siRNA designs leverage the company's novel, clinically validated and RNA-focused discovery and development platform. In this publication, Wave's siRNAs are compared to reference molecules based on siRNAs from a commercial company with a clinically proven track record in RNAi.

08:41 EDT Hanmi Financial releases 2022 annual shareholder letter - Hanmi Financial Corporatio announced the release of its 2022 annual letter to shareholders authored by President and Chief Executive Officer Bonnie Lee. "In 2022, the Hanmi team demonstrated the value of consistent execution against winning growth initiatives, even during times of economic volatility. We finished the year with record financial performance and a strong capital base, outperforming many of our peers across numerous metrics. As we navigated an uncertain economy that was adapting to rapidly rising interest rates, we maintained focus on our customers, ensuring that we were providing the right products and services to meet their needs and strengthen our portfolio... Our Competitive Advantage is Our Team. Hanmi's outperformance is directly attributable to our ability to work cohesively as a team. We do this by focusing on client relationships, harnessing our competitive nature, and most importantly, respecting open communication. Sharing ideas and constructively challenging one another enables us to be nimble, agile and creative as we serve varied communities with differing needs.... This approach is delivering results with the majority of our geographic regions and business units delivering increased production during 2022... Focused on Community and Growth. Our dedication to effectively serve our customers and the communities we operate in helps us to deliver attractive returns on your investment in Hanmi. That remains a top priority for all of us at Hanmi... Managing Through Uncertain Times From our earliest days, we have dedicated ourselves to serving our communities. That dedication is part of our foundation and continues to run through everything we do. What began with much-needed loans and banking services for underserved Korean American immigrants in Los Angeles has now grown into the second largest Korean American bank with $7.4 billion in assets and operations in nine states... When two other banks were taken over by the government in early March, we found ourselves again reaching out to customers. While our intent was to assure our customers that our bank was in very strong financial shape, I was especially moved as some of our customers asked me what they could do for us. This is truly an example of the deep relationships we have built over the years. Looking Forward. As we begin our fifth decade in 2023, Hanmi is well positioned to build on this great legacy. Your Bank is in a very strong financial position, with ample liquidity and excellent credit quality. Importantly, our banking relationships continue to be centered around the needs of individuals and small businesses, South Korean companies operating in the U.S., and real estate investors. The relationship-banking approach used in our humble beginnings continues to help us build a broad, diversified customer base.

08:39 EDT Clearmind Medicine engages CRO for CMND-100 trial - Clearmind Medicine announced additional preparations to facilitate the commencement of the company's clinical trial and engaged a contract research organization, or CRO to provide support for the company. The CRO will act as a project manager, provide support in regulatory affairs, site selection and initiation, recruitment support, clinical monitoring, data management and more. The company's upcoming first-in-human clinical trial will evaluate the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder. CMND-100 is Clearmind's novel psychedelic-derived drug, based on its proprietary MEAI molecule.

08:37 EDT Allstate estimates March catastrophe losses $1.17B - The Allstate Corporation announced estimated catastrophe losses for the month of March of $1.17B or $927M, after-tax. Catastrophe losses for March events were estimated at $1.26B , related to 10 events, with approximately 75% of the losses related to three wind events, partially offset by favorable reserve reestimates for prior events. Catastrophe losses for the first quarter totaled $1.69 billion, pre-tax. During the month of March, the Allstate brand implemented auto rate increases of 7.6% across 10 locations, resulting in total brand premium impact of 0.5%. "Allstate continued to implement significant auto insurance rate actions as part of our comprehensive plan to improve profitability. Since the beginning of the year, rate increases for Allstate brand auto insurance have resulted in a premium impact of 1.7%, which are expected to raise annualized written premiums by approximately $454 million," said Jess Merten, Chief Financial Officer of The Allstate Corporation. "In addition, the California Department of Insurance recently approved our latest Allstate brand auto insurance rate increase filing of 6.9%, which we expect to implement in April and be effective in June 2023." Our implemented auto rate exhibit has been posted on allstateinvestors.com. Unfavorable prior year reserve reestimates, excluding catastrophes, totaled $27M in the first quarter with $23M attributed to commercial insurance, primarily related to business that is being exited. Beginning next quarter, we will only disclose quarterly prior year reserve reestimates, excluding catastrophes, if material

08:36 EDT Sellas Life Sciences completes Phase I trial dose escalation of GFH009 - SELLAS Life Sciences announced completion of the safety evaluation stage of the highest dose cohort of patients with acute myeloid leukemia, AML, who relapsed after or were refractory to available antileukemic therapies in its Phase 1 dose escalation clinical trial of GFH009. No further dose escalations are planned in the AML group, while dose escalation continues in the lymphoma group with the addition of a 75 mg once-a-week dose cohort, which is planned to be the highest dose level for that group. The Company is finalizing the comprehensive data analysis to determine the recommended Phase 2 dose in AML, which will be announced following review by the U.S. Food and Drug Administration. SELLAS plans to commence a Phase 2a clinical trial during the second quarter of 2023 with GFH009 in combination with venetoclax and azacitidine in patients with AML who relapsed after or are refractory to treatment with venetoclax based therapies. The trial will be a single arm open label dose ranging study with one dose level at the RP2D and one dose below RP2D. Primary endpoints will be complete response composite rate and safety, and secondary endpoints will include duration of response, event free survival, overall survival and proportion of patients proceeding to transplant. Topline data from this study are expected in the fourth quarter of 2023.

08:34 EDT TPG, AmerisourceBergen to acquire OneOncology in $2.1B transaction - TPG (TPG) and AmerisourceBergen (ABC) announced that they have agreed to acquire OneOncology, a network of oncology practices, from General Atlantic, a global growth equity firm. TPG has agreed to acquire a majority interest in OneOncology, and AmerisourceBergen will acquire a minority interest in the company. OneOncology's affiliated practices, physicians, and management team will also retain a minority interest in the company. The transaction values OneOncology at $2.1B. TPG, AmerisourceBergen, and OneOncology's affiliated practices, physicians, and management team will form a new joint venture that will acquire OneOncology from its existing shareholders, including current majority owner General Atlantic. AmerisourceBergen will purchase its minority interest in the joint venture for approximately $685M in cash, which will represent approximately 35% ownership in the joint venture. Beginning on the third anniversary of the closing of the joint venture's acquisition of OneOncology and ending on the day before the fourth anniversary of that closing, TPG will have a put option under which TPG may require AmerisourceBergen to purchase all of the other interests in the joint venture, including TPG's interest, at a price equal to 19 times OneOncology's adjusted EBITDA for the most recently ended 12-month period prior to TPG's exercise of the put option, all of which is subject to various other adjustments and qualifications. In addition, on the date that is the third anniversary of the closing and again beginning on the fourth anniversary of the closing and ending on the day before the fifth anniversary of the closing, AmerisourceBergen will have a call option to purchase all of the other interests in the joint venture, including TPG's, also at the price set forth above subject to various other adjustments and qualifications. The transaction is expected to close by the end of September 2023 and is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. Upon closing, the minority interest in OneOncology is expected to contribute a few cents to AmerisourceBergen's adjusted diluted EPS in the first 12 months following closing. Following the closing of the transaction, AmerisourceBergen intends to account for its minority interest in OneOncology using the equity method of accounting, recording AmerisourceBergen's future share of OneOncology's net income or loss in Other Income, net.

08:33 EDT ContraFect presents CF-370 data at annual EECMID meeting - ContraFect Corporation announces presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant, XDR, strain of Pseudomonas aeruginosa. These data were recently presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases, ECCMID, Annual Meeting held from April 15-18, 2023 in Copenhagen, Denmark. "The data presented on CF-370 at ECCMID should not be understated. As a physician-scientist who has treated hundreds of immunocompromised patients with either hospital-acquired or ventilator-associated pneumonia, the efficacy of CF-370 against an XDR strain of Pseudomonas in neutropenic animals provides hope for patients struggling to fight against life-threatening, resistant pathogens with a compromised immune system," said Roger Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. "Combined with the data from the presentations of CF-370's novel mechanism of action against the Gram-negative ESKAPE pathogens, we believe the potential for CF-370 to significantly improve clinical outcomes in HAP/VAP patients continues to dramatically increase."

08:32 EDT iCoreConnect announces PDA endorsement of iCore HIPAA, iCoreExchange - iCoreConnect announced the Pennsylvania Dental Association endorsement of iCoreHIPAA HIPAA-compliance platform and iCoreExchange HIPAA-compliant email for dental practices.

08:22 EDT Griffon raises share repurchase authorization, declares $2.00 special dividend - Also, the Griffon board approved two actions to return additional capital to shareholders. First, Griffon increased its share repurchase authorization to $258M from the prior unused authorization of $58M. Second, the Griffon board declared a special cash dividend of $2.00 per share, payable on May 19 to shareholders of record as of the close of business on May 9.

08:21 EDT ENGlobal director Mark Hess retires - ENGlobal announced that Mark Hess, the Company's former CEO, has notified the Company of his decision to retire, effective April 20, as a member of ENGlobal's Board of Directors.

08:20 EDT Ocean Biomedical announces notice of allowance for U.S. patent application - Ocean Biomedical announced that its Scientific Co-founder Dr. Jack A. Elias, received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for his U.S. patent application covering a therapeutic molecule that Ocean Biomedical is working to advance into the clinic for patients suffering from pulmonary fibrosis. Discoveries in recent years by Ocean Biomedical's Scientific Co-founder, Dr. Jack A. Elias, and his colleagues at Brown University, have revealed a new target and a new pathway for treating pulmonary tissue damage in Idiopathic Pulmonary Fibrosis. This patent allowance covers pulmonary fibrosis caused by multiple conditions including: idiopathic pulmonary fibrosis, genetic pulmonary fibrosis such as Hermansky-Pudlak Syndrome, chemotherapy and radiation-induced pulmonary fibrosis, and exposure-induced interstitial lung diseases including asbestosis and silicosis. Ocean Biomedical's novel approach to treating pulmonary fibrosis - a condition with no disease modifying agents currently available - is focused on inhibiting Chitinase 1 with patented "OCF-203." Chit1 is also a critical biomarker in Scleroderma-associated interstitial lung disease and plays a role in bleomycin- and IL-13-induced pulmonary fibrosis. In four pulmonary fibrosis animal models, Ocean Biomedical's OCF-203 has shown an 85% - 90% reduction in collagen accumulation. The results of this antifibrotic in the bleomycin model can be seen in the diagram below. Results also showed efficacy in the pale-ear mouse model of HPS, including impressive reductions in fibrosis. As a result, efforts are now moving towards IND-enabling studies.

08:15 EDT Daxor announces new data from Duke University on BVA-100 blood test - Daxor Corporation announces new data from Duke University Medical Center validating the benefits of the Company's BVA-100 blood test in optimizing individualized therapy for advanced heart failure patients. Data were presented at the 43rd International Society for Heart and Lung Transplant, ISHLT, Annual Meeting and Scientific Sessions, which brought together the world's leading experts in heart and lung transplant held at the Colorado Convention Center, from April 19-22, in Denver, CO. Highlights from the three studies included: "Differences in Pressure-Volume Relationship Between Obese and Non-Obese Patients with Advanced Heart Failure" - This prospective study examined the pressure-volume relationship using right heart catheterization to measure pressures, BVA and clinical assessment in obese heart failure patients. Findings showed no significant correlation between blood volume as measured by BVA and pressure measures in the obese group, highlighting why these patients may be particularly difficult to effectively manage. "Relationship Between Blood Volume Measures and Cardiopulmonary Exercise Testing Performance in Advanced Heart Failure" - The study evaluated the impact of congestion in patients who underwent cardiopulmonary exercise testing with invasive hemodynamic assessment and BVA. Results showed moderate to no correlation between BVA measures and invasive assessment. "Differences in Cardiopulmonary Exercise Performance Between True Anemia and Hemodilution in Patients with Advanced Heart Failure" - Results showed patients with hemodilution had worse cardiopulmonary performance compared to patients with true anemia. Anemia is a common coexisting condition in patients with advanced heart failure. Distinguishing between true anemia and hemodilution guides the right therapeutic approach.

08:14 EDT XPO Logistics appoints Dave Bates as COOOld Dominion - XPO announced that Dave Bates is joining the company as chief operating officer, North American LTL, effective April 21, 2023. Bates joins XPO from 27 years with Old Dominion Freight Line, Inc., where he was responsible for all day-to-day operations in North America for the last 12 years as senior vice president, operations.

08:12 EDT Fabletics expands resale program via thredUP's Resale-as-a-Service - Fabletics, YITTY, and thredUP announced the expansion of Fabletics' resale program that now allows customers to shop secondhand Fabletics and YITTY products directly from its website. This is an expansion of its current program with thredUP that launched in July 2021, which allows customers to resell gently worn items for Fabletics shopping credit. The resale program is powered by thredUP's Resale-as-a-Service.

08:10 EDT Dare announces initiation of subject enrollment in Phase 1 thermography study - Dare Bioscience announced initiation of screening and enrollment for a Phase 1 clinical study using thermography to assess the pharmacodynamic and pharmacokinetic characterization of Sildenafil Cream, 3.6%, a late-stage product candidate being developed as a potential new treatment for female sexual arousal disorder, FSAD. The quantitative pharmacokinetic and pharmacodynamic temperature data captured in a clinic setting in the study are expected to complement the patient reported outcome data collected in the ongoing Phase 2b RESPOND study, where the women use Sildenafil Cream in their home setting. During the thermography study, vulvar temperature, a surrogate for vulvar blood flow, will be recorded by thermography in a clinic setting. Increasing blood flow to the genital tissue, as Sildenafil Cream is designed to do, has the potential to improve genital arousal response and overall sexual experience for women. Unlike the oral formulations of PDE-5 inhibitors, Sildenafil Cream is designed to be applied locally to the vaginal tissue prior to sexual activity to facilitate vasodilation and increase blood flow directly to the genital tissue to improve the physical arousal response to address the lack of those genital arousal sensations commonly associated with FSAD. "We are excited to announce that enrollment is underway in this important supplemental thermography study," said Sabrina Martucci Johnson, President & CEO of Dare Bioscience. "This study has the potential to provide additional quantitative data regarding the ability of our cream formulation of the active ingredient sildenafil to increase genital blood flow, as assessed by vulvar temperature. These data are expected to complement forthcoming clinical findings from our Phase 2b RESPOND trial in preparation for a Phase 3 program."

08:08 EDT Enphase Energy expands IQ8 microinverter deployments in Michigan - Enphase Energy announced that installers of Enphase products in Michigan have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters. "We're lucky to work with the leading solar installers across Michigan to provide homeowners with high-quality and reliable home energy products like the IQ8 Microinverter," said Ken Fong, vice president of sales, North America, at Enphase Energy. "Together, we are driving the transition to clean energy with best-in-class customer service and enabling energy independence at a time when it's needed most."

08:07 EDT Twist Bioscience teams with Astellas for drug discovery and development. - Twist Bioscience (TWST) announced a collaboration with Astellas Pharma (ALPMY) by which Astellas will license a suite of Twist's VHH antibody libraries to be used by Astellas for drug discovery and development. "We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ability to meet the varying needs of our customers and support their success," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "This latest collaboration with Astellas demonstrates how Twist can enable our customers to grow their pipelines both externally with our antibody discovery services and by supporting their internal discovery with our highly specific and potent antibody libraries." Under the terms of the agreement, Astellas will license a suite of Twist's VHH libraries for a period of five years and will use the libraries to conduct research and development activities. Twist will receive an upfront payment and will be eligible to receive annual maintenance fees and fees per product through payments associated with specific clinical and commercial milestones. Twist will also be eligible to receive royalty payments on product sales. Twist VHH Antibody Libraries

08:07 EDT Proterra announces appointment of Goodwin as Chief Information Officer - Proterra (PTRA) announced the appointment of Dustin Goodwin as Chief Information Officer, CIO. As Proterra's Chief Information Officer, Dustin joins the company's Leadership Team and will oversee all information technology programs and systems across the organization. Prior to joining Proterra, Goodwin served as CIO of Icahn Enterprises (IEP) where he led technology and cybersecurity operations for a $20B AUM investment firm and privately held companies across multiple industries.

08:04 EDT Potbelly announces refranchising initiative for 2023 - Potbelly has prioritized refranchising in 2023, aiming for approximately 25% of its corporate locations to convert during the next three years. As a launching off point for the refranchising program, the brand recently signed a multi-unit deal for New York City, which calls for 13 new shops over the next eight years, and the refranchise of eight shops. Ownership of the shops has been fully transferred to United One Group, an experienced franchise group led by CEO Paramjit Josan and Chief Development Officer Manny Singh. Combined, the UOG team has over 75 years of restaurant experience, developing and operating fast casual concepts, quick service restaurants and sandwich-specific brands, as well as other hospitality-focused businesses, in the Manhattan region. Beyond refranchising, the brand's U.S. growth plans through franchising call for significantly advancing its national footprint. Potbelly is focused on a 10% annual new unit growth rate by 2024, with accelerated expansion in the years to follow. The company has set a goal of reaching 2,000 total units in the next eight to 10 years, with at least an 85% franchise system. As Potbelly escalates its franchising initiative across the country, it is focused on awarding development agreements to talented multi-unit operators that have proven experience in developing and operating multi-unit restaurant and retail brands. The prioritization of franchise growth supports the brand's 'Traffic Driven' Profitability Strategic Plan, which includes recent Tech Stack rollouts and implementation of a new menu.

08:03 EDT Pacira partners with the Invited Celebrity Classic - Pacira BioSciences and the Invited Celebrity Classic, an officially sanctioned PGA TOUR Champions event, announced a partnership naming Pacira's pain management device, iovera degrees , as The Official Non-Opioid Pain Management Partner of the tournament and other upcoming golf events. The partnership aims to raise awareness of the role of iovera degrees to treat chronic and acute pain. iovera degrees is a handheld device that provides non-medicated pain control by applying focused cold therapy to a specific nerve to interrupt its ability to transmit a pain signal.

08:03 EDT Huntington Bancshares sees increasing CET1 to high end of 9%-10% range by YE - Says share repurchases not expected in 2023. Sees FY NII up 6%-9% vs. prior guidance of up 8%-11%. Sees noninterest income flat to down 2% vs. prior guidance of about flat. Sees FY expense ex-items up 1%-3% core underlying, with net charge offs at the low end of 25-45bps through the cycle target. Comments taken from Q1 earnings conference call presentation slides.

08:02 EDT Mobiquity Technologies integrates ad targeting tech into ATOS 2.0 - Mobiquity Technologies announces the integration of advanced AI-powered ad targeting technology into its ATOS 2.0 solution. This enhancement will enable advertisers to optimize their ad placements in real-time, ensuring greater precision and improved campaign performance across multiple platforms.

07:56 EDT AT&T targets net debt-to-adjusted EBITDA ratio of 2.5x range by early 2025

07:54 EDT Iris Energy increases operating hashrate to 4.6 EH/s - Iris Energy provided an update on the installation of its 5.5 EH/s of operating capacity. Iris Energy is pleased to advise that it has increased its operating hashrate from 3.6 EH/s to a current level of 4.6 EH/s. All remaining 0.9 EH/s of miners have been delivered and are pending installation. 160MW of data centers is available immediately, with commissioning of the first 20MW at Childress expected imminently. The Company is pleased to advise that it has been refunded $18.4 million in deposits by AEP Texas. These deposits were previously paid by the Company to AEP Texas and have now been released following energization of the 600MW bulk power substation at Childress and completion of the connection of the site to the ERCOT grid. The Company also advises that on April 18, 2023, an entity affiliated with Mr. Michael Alfred, a director on the Company's Board of Directors, acquired an additional 50,000 of its ordinary shares for consideration of approximately $232,530. Since March 13, 2023, the relevant affiliated entity has acquired 480,461 ordinary shares in aggregate for total consideration of approximately $1,515,783.

07:48 EDT Union Pacific maintains FY23 guidance - For FY23: Carloads to exceed Industrial Production; Current Industrial Production forecast: -0.7%; Operating ratio improvement; Pricing dollars in excess of inflation dollars. Capital Allocation: Capital spending less than 15% of revenue; Capital plan of $3.6B; Long term dividend payout target of ~45% of earnings; Excess cash to share repurchases.

07:44 EDT Webster Financial sees FY23 loan growth 4%-6%, core deposit growth 8%-10% - Sees FY23 NII $2.375B-$2.425B non-FTE, fees in the range of $375M-$400M, expenses $1.2B-$1.225B. Sees FY efficiency ratio about 40% and tax rate 22%-23%. The firm's long-term CET1 capital ratio target is 10.5%. Comments taken from Q1 earnings conference call presentation slides.

07:38 EDT Blue Water to acquire ENTADFI from Veru for $100M - Blue Water Vaccines (BWV) announced the signing of an Asset Purchase Agreement with Veru (VERU) for the purchase of ENTADFI(R), an FDA-approved treatment for benign prostatic hyperplasia that counteracts negative sexual side effects seen in men on alternative BPH therapies. Under this Agreement, Blue Water will purchase ENTADFI(R) for a total consideration of $100 million, with $20 million upfront, paid in defined tranches through September 2024, and the possibility of an additional $80 million based on predetermined annual sales milestones. Blue Water will also assume royalty and milestone obligations under a previous asset purchase agreement, including a royalty on all sales and sales milestone payments of up to $22.5 million. In addition to all commercial materials, contracts, intellectual property, and regulatory records and filings, BWV will acquire all available inventory of ENTADFI, approximately 125,000 bottles. ENTADFI, approved by the FDA in December 2021 for the treatment of BPH in men with an enlarged prostate, combines finasteride, a traditional BPH medication, and tadalafil, a BPH and erectile dysfunction medication, into a once daily pill. This allows patients to receive BPH medication without the negative side effects of traditional medication and has proven both safe and effective in multiple clinical trials prior to its FDA approval. In a pivotal Phase 3, double blinded, parallel-design clinical trial, 696 men, including those with co-morbid conditions, were randomized to initiate either tadalafil plus finasteride or placebo with finasteride over 26 weeks. Tadalafil and finasteride administered together demonstrated statistically significant improvement in the signs and symptoms of BPH compared to placebo with finasteride. ENTADFI is currently available at pharmacies nationwide for prescription, but upon execution of this purchase, Blue Water intends to optimize sales, distribution, and marketing strategies to maximize access to ENTADFI for BPH patients. Through this transformative acquisition, Blue Water expands to become a broader pharmaceutical company and will rely on its experienced management and leadership to drive success. In January 2023, Frank Jaeger joined Blue Water as Vice President of Marketing and Business Development and is expected to lead commercialization and sales of ENTADFI with his significant experience in men's health products, such as JATENZO and AndroGel 1.62%. In his new role at Blue Water, Mr. Jaeger is expected to lead the growth and development of ENTADFI with his expertise and knowledge within both the drug commercialization and men's health spaces. To reflect the company transformation and robust pipeline, spanning multiple sectors, the Company's Board of Directors has approved a corporate name change and rebranding to Blue Water Biotech. The name change is expected to take effect during, and rebranding activities will continue through, the second quarter of 2023. Prior to effectuating the name change, the Company's common stock will continue to trade under the ticker symbol NASDAQ: BWV.

07:35 EDT F5 Networks reducing global headcount by about 9% or 620 positions - As part of its Q2 results yesterday, the company stated: "F5 announced today that it is reducing its global headcount by approximately 620 employees, or approximately 9% of its total workforce. These workforce-related actions are expected to be completed by April 21, 2023 with the exception of the Company's EMEA and parts of its APAC regions where employees will continue the consultation process over the coming weeks, as required by local laws. The Company estimates that these headcount reductions will result in annualized savings of approximately $130 million. The Company expects it will incur approximately $45 million in severance benefits costs and other charges related to these actions in fiscal year 2023. Additionally, the Company will reduce, and in some cases, eliminate portions of its facilities footprint, as well as reduce costs by applying additional scrutiny on discretionary projects, further reducing travel, and substantially reducing the size of its corporate bonus pool in 2023." CEO Francois Locoh-Donou noted: "Given the current demand environment however, we are taking action to reduce our operating costs while prioritizing initiatives and innovations that will deliver the most benefit to our customers."

07:34 EDT Malibu Boats appoints Black as Interim Chief Financial Officer - Malibu Boats announced the appointment of David Black as Interim Chief Financial Officer, effective April 19, 2023. Malibu's current Chief Financial Officer, Wayne Wilson has notified the Company of his resignation to pursue a similar role at a private equity-backed private company in Knoxville, Tennessee. Wilson will actively serve in an advisory role and assist with the transition through May 12, 2023. The Board of Directors has initiated a search for Wilson's successor. Black has served as Malibu's Corporate Controller since November 2020, having previously served as the Company's Director of Internal Audit since 2017.

07:26 EDT Novartis presents new five-year data on Kesimpta - Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta. A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified. These data will be presented at the American Academy of Neurology, AAN, Annual Meeting held in Boston and virtually on April 22-27, 2023. Additionally, brain volume change remained low with Kesimpta treatment over five years, and overall, patients initially randomized to Kesimpta had lower levels of brain volume loss at year five than those initially randomized to teriflunomide. The separate analysis of the ALITHIOS extension data showed consistent safety results of Kesimpta for people with RMS following up to five years of treatment2. The overall rates of adverse events and serious AEs were consistent with the core Phase III trials. Most COVID-19 cases were mild to moderate in severity and non-serious, and 98.6% of patients treated with Kesimpta recovered, recovered with sequalae, or were recovering from COVID-192. Most infections resolved without discontinuing Kesimpta treatment. The overall rate of serious infections also remained stable with no increased risk over five years. Mean serum immunoglobulin G levels remained stable up to five years of treatment and the majority of patients had lgG levels above the lower limit of normal. There were six fatal cases due to serious infections.

07:14 EDT KeyCorp sees FY23 NII down 1%-3% vs. previous view up 1%-4% - Sees loans up 6%-9%, deposits flat to down 2%, noninterest income down 1%-3%. Sees FY23 noninterest expense relatively stable, and a GAAP tax rate of 20%-21% vs. prior view of 19%-20%.

07:13 EDT Delta 9 Cannabis announces second year of operation of mobile cannabis store - DELTA 9 CANNABIS announced it is in its second year of operation for its mobile store and has expanded its summer schedule to attend four music festival and events with several additional events still pending. Delta 9 has plans to attend between 8-10 events this season in 2023. In 2022 Delta 9 became the first company to launch a mobile cannabis store in Canada, licensed by the Liquor Gaming and Cannabis Authority of Manitoba to sell cannabis on-site at major Manitoba festivals. In 2023 the Company's mobile store plans to attend the 2023 Dauphin Countryfest, Rockin the Fields Minnedosa music festival, Super Spike Volleyball Tournament and Real Love Summerfest, along with other events which have yet to be finalized.

07:12 EDT KeyCorp reiterates long-term targets - In the long term the company expects: positive operating leverage, cash efficiency ratio of 54%-56%, net charge-offs to average loans 40-60 basis points and ROTCE 16%-19%. Guidance taken from Q1 investor presentation slides.

07:12 EDT Vertex Energy appoints Doug Haugh as Chief Commercial Officer - Vertex Energy announced that it has appointed energy and technology industry veteran Doug Haugh as Chief Commercial Officer of Vertex Energy, effective April 17, 2023. In his new role, Doug will provide strategic direction for all commercial operations spanning from feedstock to finished products, driving the Company's growth initiatives.

07:11 EDT Surmodics:1st patient enrolled in PROWL registry study using Pounce Thrombectomy - Surmodics announced enrollment of the first patient in PROWL, the Pounce Thrombectomy System Retrospective Registry. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce system for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. The registry will collect real-world efficacy and safety outcomes data for endovascular interventions using the Pounce system for up to 500 patients at up to 30 sites. Dr. Sean Lyden, Chairman of the Department of Vascular Surgery, Cleveland Clinic, and Dr. Joseph Campbell, Interventional Cardiologist, OhioHealth, are National Co-Principal Investigators. The first site to enroll a patient in the registry study was Baton Rouge General Medical Center, Baton Rouge, La. "We are delighted to be the first site to enroll a patient in the PROWL registry," said Dr. Joseph Griffin, Vascular Surgeon, Vascular Specialty Center, LLC and Baton Rouge General Medical Center. "In our experience, the Pounce system promptly removes peripheral arterial clot in a single treatment session while reducing the need for thrombolytic drugs and subsequent ICU stays. We're eager to help track outcomes in this important study." "We've long needed better tools to help us resolve acute limb ischemia in a simple and effective manner, without the use of multiple adjunctive treatments," he added. "In this respect, our experience with the Pounce system has been quite positive."

07:09 EDT MidCap Financial Investment amends, extends revolving credit facility - MidCap Financial Investment Corporation has amended and extended its senior secured, multi-currency, revolving credit facility. Lender commitments under the Facility will remain $1.705 billion until December 22, 2024 and will decrease to $1.550 billion thereafter. The final maturity date under the Facility was extended by over two years from December 22, 2025 to April 19, 2028. The primary benchmark rate was changed from LIBOR to SOFR and the spread under the Facility was slightly reduced. The remaining material terms of the Facility will remain unchanged.JPMorgan Chase Bank, N.A., Truist Securities, Inc., BMO Capital Markets Corp., and MUFG Bank, LTD. are Joint Bookrunners and Joint Lead Arrangers on the Facility. JPMorgan Chase Bank, N.A is the Administrative Agent on the Facility.

07:08 EDT Nabors Industries partners with Corva for digital drilling control - Nabors Industries and Corva announced a strategic technology partnership to provide a digital and automation offering to the global drilling industry. Integrating Corva's industry leading App Store and Dev Center with Nabors' SmartROS universal drilling rig controls and automation system is expected to deliver solutions that rapidly scale process and machine automation, enhance remote project oversight and streamline data exchange and collaboration across any AC rig fleet. Nabors and Corva seek to simplify the execution of automation on any AC rig. Current deployments of SmartROS include more than 124 Nabors rigs in the Lower 48, Latin America and the Middle East, as well as 15 non-Nabors rigs. Corva features more than 100 Apps and Dashboards that automate, monitor and optimize drilling processes. Using SmartROS, Corva extends rig control and real-time data pipelines from the wellsite to the E&P company's back office and mobile devices, enabling customers to drill safer and more effectively.

07:08 EDT ObsEva announces change of central securities depositary - ObsEva intends for its common shares to be traded under a new International Securities Identification Numbers beginning on April 25, 2023. ObsEva's common shares were delisted from the Nasdaq Capital Market, effective March 23, 2023, and a Form 25 was filed on March 27, 2023 to remove the registration of ObsEva's common shares under Section 12(b) of the Securities Exchange Act of 1934, as amended. ObsEva intends to file a Form 15 with the Securities and Exchange Commission suspending its reporting obligations under Section 15(d) of the Exchange Act on April 26, 2023. As a result, ObsEva's common shares are expected to be no longer eligible to settle through the systems operated by The Depository Trust Company, which so far has operated as the central securities depositary for ObsEva's common shares. Additionally, it is expected that ObsEva's common shares will cease trading on the OTC Pink Sheets Marketplace under the symbol "OBSVF". ObsEva has taken steps to provide that SIX SIS will act as the central securities depositary for ObsEva's common shares. SIX SIS is a central securities depositary for securities traded on SIX Swiss Exchange, where ObsEva's common shares are listed under the ticker symbol "OBSN". Once the switch from DTC to SIX SIS is completed, the common shares will trade under a new ISIN. April 24, 2023 is the last day ObsEva's common shares will be traded under CUSIP H5861P103 and ISIN CH0346177709. The next day, April 25, 2023, ObsEva's common shares will be tradable on SIX Swiss Exchange under ISIN CH1260041939.

06:56 EDT Lannett announces NYSE to commence proceedings to delist company common stock - Lannett announced that it received a written notice from the NYSE, notifying the company that the NYSE will commence proceedings to delist the company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15,000,000 over a consecutive 30-trading day period. The NYSE suspended trading in the company's common stock immediately after market close on April 19. The company's common stock will begin trading in the over-the-counter market commencing on April 20. The common stock will retain the ticker symbol (LCI).

06:50 EDT D.R. Horton reports Q2 home sales revenues of $7.4B on 19,664 homes closed - Reports Q2 net sales orders of 23,142 homes, with an order value of $8.6B. At March 31, 2023, the company had 43,600 homes in inventory, of which 24,800 were unsold. 6,400 of the company's unsold homes at March 31, 2023 were completed. The company's homebuilding land and lot portfolio totaled 547,000 lots at the end of the quarter, of which 25% were owned and 75% were controlled through land and lot purchase contracts.

06:48 EDT Comerica sees 2023 average loans up 8%-9%, NII up 6%-7% vs. 2022 - Sees 2023 average deposits down 12%-14%, with noninterest income up 6%-7% and noninterest expenses up 7%. Sees FY23 tax rate roughly 23% and CET1 ratio of about 10%.

06:46 EDT Dollar General names Kelly Dilts as CFO, succeeding John Garratt - Dollar General announced the promotion of Kelly Dilts to Executive Vice President and CFO, effective May 1. The company's current President and CFO John Garratt will retain his role as President until his planned retirement on June 2. Since joining Dollar General in July 2019, Dilts has served as Senior Vice President, Finance with responsibility for financial planning and analysis; procurement; margin planning and analytics; decision science and analytics; and investor relations.

06:42 EDT Herc Holdings backs 2023 adjusted EBITDA view $1.45B-$1.55B

06:37 EDT AT&T says on track to achieve $6B-plus run-rate cost savings target this year

06:26 EDT KBR awarded engineering, design services contract from Chemours - KBR (KBR) today it has been awarded an engineering and design services contract from Chemours (CC) to increase capacity and advance technology for its Nafion ion exchange materials platform. The contract is part of Chemours' $200M investment to expand the Nafion membranes and dispersions technology platform to support the growing hydrogen economy.

06:02 EDT Uber, Cartken expand sidewalk robot deliveries to Virginia - Uber Technologies and Cartken, an AI-powered robotics company, announced an expansion of their partnership to include food deliveries via automated robots in Fairfax, Virginia. Uber Eats consumers at Mosaic District will have the opportunity to have orders delivered by Cartken's self-driving robot. Starting April 20, Uber and Cartken will begin operating with select merchants at Mosaic District, a shopping and dining district owned and operated by EDENS. At launch, merchants like Our Mom Eugenia, Pupatella, and RASA, will participate in the program.

05:51 EDT Coinbase receives license to operate in Bermuda - In a blog post on Wednesday, Coinbase disclosed that it has received a license to operate in Bermuda. The company said: "Bermuda was chosen as one of our international hubs as the BMA is a highly respected and experienced financial regulator that is led by a world-class executive team and board of directors." TheFly notes that CoinDesk reported on Wednesday that CEO Brian Armstrong has indicated that if the U.S. regulatory environment for the industry does not become clearer, the crypto exchange will consider moving away from the U.S. Reference Link

05:06 EDT Payoneer Global collaborates with Zoho on payment solutions - Payoneer announced its collaboration with Zoho, a global technology company which provides a range of software solutions to businesses. The collaboration will enable Payoneer to provide innovative payment solutions to businesses using Zoho Books, the cloud accounting platform, with plans to expand to other parts of the Zoho product offering. The collaboration will benefit small and medium-sized businesses and freelancers working globally in India, Australia, New Zealand, the UK, and the Philippines, with plans to expand the offering into new markets in the future. Businesses will be able to select Payoneer as a payment solution when invoicing their clients, and their funds will be received in the Payoneer account. Businesses in India, Australia, New Zealand, the UK, and the Philippines can then hold the funds in different currencies, spend online, or pay suppliers. Businesses in India can withdraw their funds automatically to their local bank account and download their digital FIRC. Payoneer's payment solution will be available as an extension which can be installed from Zoho Marketplace, enabling businesses to invoice their customers and receive payments into their Payoneer account. In addition to this, the automated payment reminders in Zoho Books will help businesses to reduce the number of late payments. Payoneer's customers will have access to Zoho Books, followed by other products from Zoho's finance suite in the coming months, making this a one-stop solution for businesses.